Genomic, Transcriptomic, and Epigenomic Correlates of Outcome Among Patients with High-risk Neuroblastoma Treated with Anti-GD2 Antibody
Session Number
BIO 09
Advisor(s)
Mark Applebaum, University of Chicago
Discipline
Biology
Start Date
17-4-2024 10:45 AM
End Date
17-4-2024 11:00 AM
Abstract
Neuroblastoma is the most common extracranial solid tumor in childhood. Those with high-risk (HR) disease have a long-term survival rate of approximately 60%. Patients with high-risk neuroblastoma treated with the Anti-GD2 antibody have demonstrated significant improvements in outcome. Despite these improvements, approximately 30-35% patients continue to experience poor clinical outcomes. We aim to develop a biomarker of outcome which may identify patients who may benefit from novel approaches. RNA-Seq data from GMKF and TARGET databases (n = 29) was utilized to identify gene expression patterns associated with outcome from patients with high-risk neuroblastoma treated with Anti-GD2 antibody.
Univariate cox regression models were used for each individual gene. Genes whose expression is identified as significantly associated with EFS (event-free survival) were evaluated using multivariable Cox modeling as well as Kaplan-Meier analysis. We identified 16,430 genes associated with outcome. However, after accounting for multiple testing, none of the genes were statistically significant. We identified eight genes whose high expression was significantly and independently associated with worse clinical outcome in patients with high-risk neuroblastoma treated with Anti-GD2. These genes have the potential to be used as biomarkers of outcome, however, a larger sample size is needed for them to be statistically significant.
Genomic, Transcriptomic, and Epigenomic Correlates of Outcome Among Patients with High-risk Neuroblastoma Treated with Anti-GD2 Antibody
Neuroblastoma is the most common extracranial solid tumor in childhood. Those with high-risk (HR) disease have a long-term survival rate of approximately 60%. Patients with high-risk neuroblastoma treated with the Anti-GD2 antibody have demonstrated significant improvements in outcome. Despite these improvements, approximately 30-35% patients continue to experience poor clinical outcomes. We aim to develop a biomarker of outcome which may identify patients who may benefit from novel approaches. RNA-Seq data from GMKF and TARGET databases (n = 29) was utilized to identify gene expression patterns associated with outcome from patients with high-risk neuroblastoma treated with Anti-GD2 antibody.
Univariate cox regression models were used for each individual gene. Genes whose expression is identified as significantly associated with EFS (event-free survival) were evaluated using multivariable Cox modeling as well as Kaplan-Meier analysis. We identified 16,430 genes associated with outcome. However, after accounting for multiple testing, none of the genes were statistically significant. We identified eight genes whose high expression was significantly and independently associated with worse clinical outcome in patients with high-risk neuroblastoma treated with Anti-GD2. These genes have the potential to be used as biomarkers of outcome, however, a larger sample size is needed for them to be statistically significant.